C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$6.32 USD
-0.11 (-1.71%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.33 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Brokerage Reports
0 items in cart
C4 Therapeutics, Inc. [CCCC]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CFT7455 Data Support Accelerated Approval Pathway in BCMA Refractory Patients, Indicate Opportunities in Early Lines
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on CFT7455 As C4 Culls BRD9 Program; Reiterate Buy; PT Down to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Data Readouts in 2H 2023 Might Test the Strength of Torpedo; Reiterate Buy and Lowering PT to $17 from $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on CFT8634 C4?s BRD9 Degrader; Reit. Buy; PT Down to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Insights on the Phase 1/2 CFT8634 Data in 2H 2023; Reit. Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cereblon Dumps Thalidomide for Better Degrons?Takeaways From The 5th Targeted Protein Degradation Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CFT1946, A New Foe for the Undruggable BRAF Mutant Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Treatment Paradigm Pulse-A Prospective Look at EGFR Inhibitors in NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Phase 1/2 Study of CFT8634-Teachings from PALETTE
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Learnings From FASEB?s Ubiquitin Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on CFT1946 in BRAF V600X-Driven Cancers as C4 Plans for a Phase 1 in 2H 2022; Reit. Buy; Lower PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR Data Indicates CFT7455?s Deep Degradation Potential with On-Target Safety Issues Guiding Future Trial Design
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Considerations For CFT7455 Data Readout at AACR in April 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CFT7455 and CFT8919 Setting the Stage for Protein Degradation Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CFT7455?s New Data Supports Further Clinical Development in NH L? Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CFT8919 Preclinical Data Bodes Well for the Platform - Our Insights
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: C4 Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hone, Seek, Target and Destroy Disease-Causing Proteins Using TORPEDO; Initiate With Buy and $63 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
|